SubsidieMeestersDiagnose Alzheimer’s disease with isotopes
The project aims to utilize high-precision stable isotope measurements of metals to detect early stages of Alzheimer's disease, combining geochemistry with medical science for potential patenting.
Projectdetails
Introduction
During the course of the PRISTINE proposal, we have developed the first high precision, high sensitivity stable isotope measurements for a variety of vital elements, including Zn and Cu.
Technical Advances
With these technical advances, we realized that we could monitor stable isotopic changes within organisms. This opens up a new way to study metal homeostasis as well as new methods for detection and diagnosis of diseases, in particular Alzheimer's disease.
Future Exploration
In DAI, we will further explore and make use of these unique technical advances to demonstrate the feasibility of using stable isotope geochemistry of metals to detect the early stages of Alzheimer's disease.
Methodology
To reach this goal, we will combine our technical skills developed during PRISTINE with medical science to demonstrate this proof of concept. If successful, we aim to file a patent.
Significance
This would represent a unique way to apply isotope cosmochemistry to medical science fields.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 30-11-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- INSTITUT DE PHYSIQUE DU GLOBE DE PARISpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Fluid Biomarkers for Neurodegenerative DementiasThe project aims to develop high-throughput biomarker tools for Alzheimer's and neurodegenerative diseases, enabling comprehensive analysis for diagnostics, drug discovery, and personalized medicine. | ERC Advanced... | € 2.422.973 | 2022 | Details |
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s diseaseADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Signal-enhanced MRI contrast agents for neurodegenerationThis project aims to develop and validate new magnetic resonance technologies for early, non-invasive diagnosis of neurodegenerative diseases using metabolic contrast agents. | ERC Proof of... | € 150.000 | 2022 | Details |
Environmental metal pollution revealed in archaeological human remainsPollutedPast aims to assess the impact of historical metal pollution on preindustrial populations by analyzing skeletal remains alongside natural archives from Spain and Sweden. | ERC Consolid... | € 1.999.966 | 2023 | Details |
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors. | ERC Consolid... | € 2.999.934 | 2025 | Details |
Fluid Biomarkers for Neurodegenerative Dementias
The project aims to develop high-throughput biomarker tools for Alzheimer's and neurodegenerative diseases, enabling comprehensive analysis for diagnostics, drug discovery, and personalized medicine.
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
ADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients.
Signal-enhanced MRI contrast agents for neurodegeneration
This project aims to develop and validate new magnetic resonance technologies for early, non-invasive diagnosis of neurodegenerative diseases using metabolic contrast agents.
Environmental metal pollution revealed in archaeological human remains
PollutedPast aims to assess the impact of historical metal pollution on preindustrial populations by analyzing skeletal remains alongside natural archives from Spain and Sweden.
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.
This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug developmentATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Human Antibody-enabled Cardiovascular Personalized TheranosisABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients. | EIC Pathfinder | € 3.639.665 | 2024 | Details |
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.
Human Antibody-enabled Cardiovascular Personalized Theranosis
ABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients.